Burden of rotavirus disease and cost-effectiveness of universal vaccination in the Province of Genoa (Northern Italy)

Vaccine

Volumn 27, Issue 25-26, 2009, Pages 3450-3453

  Panatto, D ^a   Amicizia, D ^a   Ansaldi, F ^a   Marocco, A ^b   Marchetti, F ^b   Bamfi, F ^b   Giacchino, R ^c   Tacchella, A ^c   Del Buono, S ^c   Gasparini, R ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b GSK   (Italy)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

Cost effectiveness; Rotavirus; Vaccination

Indexed keywords

AMOXICILLIN; ERYTHROMYCIN; ORAL REHYDRATION SOLUTION; PARACETAMOL; PENICILLIN G; PROBIOTIC AGENT; ROTAVIRUS VACCINE;

ANTIBIOTIC THERAPY; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; EMERGENCY WARD; EPIDEMIC; FECES ANALYSIS; GASTROENTERITIS; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INFANT; ITALY; MAJOR CLINICAL STUDY; NEWBORN; NONHUMAN; PEDIATRICIAN; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; ROTAVIRUS; VACCINATION; VIRAL GASTROENTERITIS;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MIDDLE AGED; MODELS, ECONOMIC; ROTAVIRUS INFECTIONS; VACCINATION;

EID: 67349222149     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.054     Document Type: Article

References (27)

1. Parashar U.D. Global illness and deaths caused by Rotavirus disease in children. Emerg Infect Dis 9 (2003) 565-572
2. Parashar U.D., Bresee J.S., and Glass R.L. The global burden of diarrhoeal disease in children. Bull World Organ 81 4 (2003) 236
3. Dennehy P.H. Transmission of rotavirus and other enteric pathogens in the home. Pediatr Infect Dis J 19 Suppl. 10 (2000) S103-S105
4. Fischer T.K., Bresee J.S., and Glass R.I. Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children. Vaccine 22 Suppl. 1 (2004) S49-S54
5. Parashar U.D., Gibson C.J., Bresee J.S., and Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 12 2 (2006) 304-306
6. Soriano-Gabarrò M., Mzrukowic J., and Vesikari T. Burden of Rotavirus disease in European Union countries. Pediatr Infect Dis J 25 Suppl. 1 (2006) S7-S11
7. Linhares A.C., Velázquez F.R., Pérez-Schael I., Sáez-Llorens X., Abate H., Espinoza F., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 371 9619 (2008) 1881-1889
8. Vesikari T., Itzler R., Matson D.O., Santosham M., Christie C.D., Coia M., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Int J Infect Dis 11 Suppl. 2 (2007) S21-S23
9. Parashar U.D., and Glass R.I. Rotavirus vaccination in Europe: the time has finally arrived. J Pediatr Gastroenterol Nutr. 46 Suppl. 2 (2008) S21-S23
10. Lorgelly P.K., Joshi D., and Iturriza Gómara M. Infantile gastroenteritis in the community: a cost-of-illness study. Epidemiol Infect 136 1 (2008) 34-43
11. Bilcke J., Van Damme P., De Smet F., Hanquet G., Van Ranst M., and Beutels P. The health and economic burden of rotavirus disease in Belgium. Eur J Pediatr 167 12 (2008) 1409-1419
12. López-de-Andrés A., Jiménez-García R., Carrasco-Garrido P., Alvaro-Meca A., Galarza P.G., and de Miguel A.G. Hospitalisations associated with rotavirus gastroenteritis in Spain 2001-2005. BMC Public Health 8 (2008) 109
13. Istat 14th Italian population census. October 21, 2001. Website: www.demoistat.it [accessed 04.09.2008].
14. Informatore farmaceutico Masson; 2008.
15. Goossens L.M., Standaert B., Hartwig N., Hövels A.M., and Al M.J. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 26 8 (2008) 1118-1127
16. Lucioni C., Alliata E., Mazzi S., and Lizioli A. I costi della meningite pneumococcica in età pediatrica. Pharmaecoeconomics-Italian Research Articles 7 (2005) 177-186
17. Ruiz-Palacios G.M., Pérez-Schael I., Velázquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354 (2006) 11-12
18. Vesikari T. RIX44141 is highly efficacious in Europe. In: Proceedings of the 24th annual meeting of the European society for pediatric infectious diseases, Basel, Switzerland; 2006. http://www.kenes.com/espid [accessed 11.09.2008].
19. Martin A., and Cortell S. Estimating utility in rotavirus gastroenteritis in children under five in the UK contributed poster presentations. Value Health 9 (2006) A208-A393
20. Giaquinto C., Callegaro S., Andreola B., Bernuzzi M., Cantarutti L., D'Elia R., et al. Prospective study of the burden of acute gastroenteritis and rotavirus gastroenteritis in children less than 5 years of age, in Padova, Italy. Infection 36 4 (2008) 351-357
21. Giacquinto C., Callegaro S., Andreola B., Bernuzzi M., Cantarutti L., D'Elia R., et al. Costi della gastroenterite da Rotavirus acquisita in comunità in età pediatrica a Padova in Italia. Pharmacoeconomics-Italian Res Articles 9 (2007) 103-111
22. The Pediatric ROTavirus European CommitTee (PROTECT). The paediatric burden of rotavirus disease in Europe. Epidemiol Infect 134 5 (2006) 908-916
23. Gianino P., Mastretta E., Longo P., Laccisaglia A., Sartore M., Russo R., et al. Incidence of nosocomial rotavirus infections, symptomatic and asymptomatic, in breast-fed and non-breast-fed infants. J Hosp Infect 48 1 (2002) 5-9
24. Gabutti G., Marsella M., Lazzara C., Fiumana E., Cavallaro A., and Borgna-Pignatti C. Epidemiology and burden of Rotavirus-associated hospitalisations in Ferrara. Italy J Prev Med Hyg 48 1 (2007) 5-9
25. Melliez H., Levybruhl D., Boelle P.Y., Dervaux B., Baron S., and Yazdanpanah Y. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 26 (2008) 706-715
26. Jit M., and Edmunds W.J. Evaluating rotavirus vaccination in England and Wales Part II The potential cost-effectiveness of vaccination. Vaccine 25 (2007) 3971-3979
27. Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity-United States, November 2007 to May 2008. Morb Mortal Wkly Rep 27 57(25) (2008) 697-700